11 news items
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
11 Jun 24
Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children, the impact of weight
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
, presented the design of Real-world Evidence of SeTmelanotide fOr Hyperphagia and ChRonic Weight ManagEment (RESTORE), the first study to assess
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
RYTM
3 Jun 24
should periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide
ev0n7ooh0n71wixncggthxkh03mxhxe38yzdjfn8c6w3ikxhzgut5
RYTM
29 Apr 24
achieved a 5% or greater reduction in BMI after 16 weeks of treatment. Hunger was also assessed daily, as self-reported by individual patients
hr8biome2tnvkojkep6x35w0zs8oc3c1ekhqz8e5sop9h732dbub
RYTM
29 Apr 24
endpoint was the proportion of patients who achieved a 5% or greater reduction in BMI after 16 weeks of treatment. Hunger was also assessed daily, as self
vgk wrszr0foiw0ymyaaatzcswfmf1klm
RYTM
26 Apr 24
(NASDAQ:RYTM) in the last three months.
Summarizing their recent assessments, the table
qvf ocu50obvn7t7gwvm2rux7gv6hn37oqc1nmrkwe6aaidvd
RYTM
24 Apr 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated
8d5zpg0lb05yd40lbjc2temj
RYTM
16 Apr 24
and discontinue setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
6br62fvc2zq4srmvy0ya enh833xcancr
RYTM
10 Apr 24
quarter vary from bullish to bearish, as provided by 5 analysts.
Summarizing their recent assessments, the table below illustrates the evolving
- Prev
- 1
- Next